Antibodies, Vaccination, HIV and ELISA

A B lymphocyte with a complementary receptor binds an appropriate antigen and can receive helper T-cell stimulation. The selected cell divides by mitosis, forming a clone. Some descendants become plasma cells that secrete antibodies; others become memory cells, allowing a more rapid and larger secondary response on later exposure.

An antibody is a protein with heavy and light polypeptide chains held together in a specific structure, including disulfide bonds. Variable regions form antigen-binding sites; constant regions have other roles. Each clone produces antibodies with the same binding specificity. Binding can agglutinate bacterial cells and promote their recognition and removal by phagocytes.

Vaccination introduces suitable antigenic material in a form intended to stimulate protective immunity without the full disease risk of the pathogen. Active immunity involves the person’s own immune response and can produce memory; passive immunity supplies antibodies directly and is usually temporary without generating the same immune memory.

When sufficient people are protected against transmission, a pathogen may spread less effectively, giving indirect protection to susceptible individuals. The threshold depends on transmission and vaccine characteristics rather than one universal percentage. Evaluate vaccine evidence through relevant comparison groups, sample sizes, confounding factors and the distinction between relative and absolute risk. Antigen variability can limit protection against new variants.

HIV is an enveloped RNA virus with attachment proteins and reverse transcriptase. After entry into a suitable helper T cell, reverse transcriptase can produce DNA from viral RNA; viral genetic information is used in host-dependent production and assembly of further virus particles.

Loss and dysfunction of helper T cells weaken coordination of immune responses. AIDS involves severe immune deficiency and susceptibility to opportunistic infections and some cancers; HIV infection and AIDS are not synonymous stages. Antibiotics do not act on the virus itself because it lacks the bacterial targets those drugs affect.

Monoclonal antibodies of one specificity can target a particular cell-associated antigen and carry a therapeutic drug, helping direct delivery. Specificity is useful but does not guarantee no side effects: targets may occur in healthy tissues or treatment effects may extend beyond binding alone. Evaluate benefits, limitations and ethical issues using evidence.

ELISA uses antibody binding and an enzyme-linked detection step. In a suitable assay, a target antigen or antibody is captured, unbound material is washed away, and an enzyme-linked reagent produces a measurable colour after substrate addition. The exact layout depends on what is being detected. Include positive and negative controls; a positive signal requires interpretation of sensitivity, specificity and possible false positives.

Try each question before opening the worked response. Use precise biological terms, connect each cause to its effect, and check units and assumptions when interpreting data.